Replies to post #2836 on Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

I might be wrong on being wrong? Delays in starting new trials and new trial sites for existing trials but perhaps less so in existing trials and sites, hopefully. Life threatening diseases I would think still need to be a priority. From FirstWord Pharma

Clinical trials hit by pandemic...
Bristol Myers Squibb, Eli Lilly and Pfizer became the highest-profile drugmakers to disclose that the COVID-19 pandemic will affect their clinical trials. Bristol Myers Squibb said that for new studies and for trials that are already under way, no new sites will be initiated nor activated until at least April 13. The company added that it has also temporarily suspended screening, enrollment and apheresis in cell therapy studies.

Meanwhile, Eli Lilly noted that it will postpone most new study starts, and temporarily suspend recruiting new patients or healthy volunteers in most ongoing trials. However, Eli Lilly suggested that previously communicated timelines for ongoing late-stage studies are not expected to slip, except for gastrointestinal indications for the experimental p19-directed IL-23 antibody mirikizumab. Further, Pfizer indicated that with the exception of certain trials recruiting patients with life-threatening conditions, it will postpone enrolment in new and ongoing global trials for three weeks